当前位置:首页 - 行情中心 - 近岸蛋白(688137) - 财务分析 - 利润表

近岸蛋白

(688137)

  

流通市值:14.92亿  总市值:32.04亿
流通股本:3267.54万   总股本:7017.54万

利润表

报告期2025-03-312024-12-312024-09-302024-06-30
公司类型通用通用通用通用
一、营业总收入33,444,619.29127,555,134.7892,079,068.4859,655,247.04
  营业收入33,444,619.29127,555,134.7892,079,068.4859,655,247.04
二、营业总成本41,376,150.08166,495,773.97115,556,413.2376,651,133.2
  营业成本12,622,698.2847,989,594.7832,652,717.3221,880,716.91
  税金及附加295,607.191,451,274.681,212,448.88799,430.34
  销售费用12,430,941.9951,933,890.0734,818,725.8323,228,529.46
  管理费用10,660,333.2249,153,756.3237,305,567.9824,506,313.56
  研发费用13,318,794.249,922,930.6233,757,447.6322,415,456.03
  财务费用-7,952,224.8-33,955,672.5-24,190,494.41-16,179,313.1
  其中:利息费用760,243.023,587,125.112,782,177.921,909,672.71
  其中:利息收入8,820,335.2336,906,796.5327,524,514.4517,846,154.11
三、其他经营收益
  加:公允价值变动收益--1,804,926.16-1,804,926.16-1,804,926.16
  加:投资收益267,479.914,569,887.114,569,887.114,569,887.11
  资产处置收益-141,603.68--
  资产减值损失(新)-8,321,843.97-32,094,508.76-19,097,136.16-14,414,916.44
  信用减值损失(新)57,960.39-2,448,524.63-3,525,505.81-2,970,046.26
  其他收益374,528.2817,497,032.8816,364,793.2115,631,660.74
四、营业利润-15,553,406.18-53,080,075.07-26,970,232.56-15,984,227.17
  加:营业外收入11,480.248,271.6348,257.147,376.2
  减:营业外支出279,966.861,186,467.8676,107.9541,718.7
五、利润总额-15,821,892.84-54,218,271.24-27,598,083.36-16,478,569.67
  减:所得税费用-4,013,489.43198,010.86-9,339,548.27-7,572,775.9
六、净利润-11,808,403.41-54,416,282.1-18,258,535.09-8,905,793.77
(一)按经营持续性分类
  持续经营净利润-11,808,403.41-54,416,282.1-18,258,535.09-8,905,793.77
(二)按所有权归属分类
  归属于母公司股东的净利润-11,808,403.41-54,416,282.1-18,258,535.09-8,905,793.77
  扣除非经常损益后的净利润-12,404,641.19-71,748,588.94-32,707,388.88-22,999,228.18
七、每股收益
  (一)基本每股收益-0.17-0.78-0.26-0.13
  (二)稀释每股收益-0.17-0.78-0.26-0.13
八、其他综合收益21,986.91-23,123.46,228.41-2,068.23
  归属于母公司股东的其他综合收益21,986.91-23,123.46,228.41-2,068.23
九、综合收益总额-11,786,416.5-54,439,405.5-18,252,306.68-8,907,862
  归属于母公司股东的综合收益总额-11,786,416.5-54,439,405.5-18,252,306.68-8,907,862
公告日期2025-04-292025-04-292024-10-302024-08-30
审计意见(境内)标准无保留意见
TOP↑